STUDY DESIGN AND METHODS: Study A: The incidence of acquired CMV transmission was prospectively investigated in 65 VLBWIs. Study B: To determine the transmission routes in 18 TT-CMVsuspected VLBWIs who had been reported in our hemovigilance system, we performed polymerase chain reaction for CMV DNA in fed breast milk and/or repository blood samples related to transfused leukoreduced blood products. Furthermore, we evaluated the identity of CMV strains in patients' urine/blood samples and fed breast milk by sequence analyses of variable CMV genes UL139 and UL146.
RESULTS: Study A: Acquired CMV infection was found in 4 of 65 VLBWIs (6.2%). Study B: CMV DNA was detected in fed breast milk for 12 of 14 TT-CMVsuspected cases, for which breast milk was available. Furthermore, CMV DNA sequence-matching rates between fed breast milk and patients' urine/blood for both UL139 and UL146 genes were 100% or nearly 100% in 11 patients. In contrast, repository blood samples for 11 of 14 patients were CMV DNA negative.
CONCLUSION: CMV is principally transmitted through breast milk in VLBWIs. The risk of TT-CMV seems to be extremely low when using leukoreduced blood products. Sequence analyses of the variable CMV genes are useful for evaluating CMV transmission routes. C ytomegalovirus (CMV) can be transmitted to newborn infants via breast milk, from other CMV-infected individuals, or via blood transfusion products. In most full-term infants, transmission usually causes no severe clinical symptoms. In contrast, transmission to preterm or very-low-birth-weight infants (VLBWIs) occasionally develops into a serious CMV disease, such as sepsis-like syndrome, probably because of the low level of transferred maternal anti-CMV antibodies and the immature state of the infant's immune system. ABBREVIATIONS: BM-CMV = breast milk-transmitted CMV; CMV = cytomegalovirus; JRCS = Japanese Red Cross Society; LOD = limit of detection; PCR = polymerase chain reaction; TT-CMV = transfusiontransmitted CMV; VLBWI = very-low-birth-weight infant Furthermore, acquired infection in VLBWIs during the neonatal period has been reported to influence the development of cognitive or motor functions later in life. [1] [2] [3] Therefore, prevention of CMV transmission to VLBWIs is clinically important. The incidence of acquired CMV infection in preterm infants in a Japanese neonatal care unit remains to be determined, although several studies have shown the incidence in other countries. [4] [5] [6] [7] In >70% of CMV-seropositive mothers, CMV DNA was found in their breast milk, although CMV DNA was undetectable in their blood. 4, 8 Thus, breast milk might be a major source of CMV transmission. In fact, a previous metaanalysis showed that 11 to 37% of infants fed CMV DNApositive breast milk were infected with CMV. 7 Although blood products could be another source of CMV transmission, it has been thought that the use of CMV-seronegative or leukoreduced blood products effectively precludes the occurrence of transfusion-transmitted CMV (TT-CMV). In fact, some previous studies have suggested, on the basis of epidemiology, that breast milk, but not transfusion, is the major route for CMV transmission. 9, 10 Furthermore, it has recently been reported that the risk of TT-CMV is extremely low under the current transfusion policy using universal leukoreduction. [11] [12] [13] [14] Nevertheless, TT-CMV tends to be clinically suspected in VLBWIs who develop CMV disease after transfusion, even if these patients were fed breast milk simultaneously.
To obtain a precise diagnosis of breast milktransmitted CMV (BM-CMV) or TT-CMV, it is helpful to show that the CMV strain found in the fed breast milk or donors' blood is the same as that detected in the patient's urine/blood. For this purpose, sequence analyses of the UL139 gene, which encodes a membrane glycoprotein, and the UL146 gene, which encodes a CXC chemokine, are useful; these genes are major hypervariable regions in CMV, 15 although the variation in the sequences of these genes is rather limited. Unfortunately, sequence analyses of CMV obtained from relevant test specimens have not been widely adopted thus far; therefore, it has been difficult to determine the transmission route.
In the present study, we evaluated the transmission route of CMV to VLBWIs. We first investigated the incidence of acquired CMV infection in preterm infants. We next examined the possibility of TT-CMV or BM-CMV in TT-CMV-suspected VLBWIs by sequencing the CMV UL139 and UL146 genes in virus obtained from the breast milk and transfused blood.
MATERIALS AND METHODS

Patients for the incidence study
To investigate the incidence of acquired CMV infection in preterm infants, a prospective study was conducted in all infants with gestational age <33 weeks or birth weight <1500 g who were born between August 2015 and January 2017 at the neonatal care unit in Kobe University Hospital (Study A). This study was approved by the Ethical Committee of the Kobe University Graduate School of Medicine (No. 160022), and written informed consent was obtained from the parents of all infants. Screening for urine CMV DNA was performed within 1 week after birth by the previously described filter method. 16 A positive result indicated congenital CMV infection. Frozen-thawed breast milk (frozen at −20 C for >24 hr) or formula milk (if the amount of breast milk was insufficient) was administered by intragastric tube until approximately 35 weeks of corrected gestational age, when infants can usually feed orally. Once the frozen-thawed breast milk-feeding period was over, infants could start fresh breast milk feeding. For infants with negative results in the initial CMV screening, urine CMV DNA detection by real-time quantitative polymerase chain reaction (PCR) was performed using a liquid urine sample obtained at least 3 weeks after birth and before starting fresh breast milk feeding. 17 A positive result indicated acquired CMV infection (Fig. 1 ).
TT-CMV-suspected patients
In the hemovigilance system, all suspected cases of transfusion-transmitted infection in the country are reported to the Japanese Red Cross Society (JRCS). With respect to TT-CMV in VLBWIs, 17 suspected cases were reported from October 2014 to April 2017. All infants had received transfusion with leukoreduced blood products before the development of CMV disease. All infants also were fed their mothers' breast milk. One infant, who was diagnosed as having congenital infection on the basis of CMV positivity in dried umbilical cord blood, was excluded from the present study. The remaining 16 cases, including 4 cases for which breast milk was not provided, were analyzed for determination of transmission route (Study B). Study B was conducted during the investigation for adverse effects of blood transfusion; review by an ethical committee is generally not required for this type of study. In addition to these 16 cases (Nos. 1-11 and 14-18 in Tables 1 and 2) , two infants with acquired CMV infection, both of whom had participated in Study A, were also included in Study B (Nos. 12 and 13 in Tables 1 and 2 ). Thus, a total of 18 cases were analyzed in Study B. PCR for CMV DNA CMV PCR analysis was performed by the JRCS Central Blood Institute. Briefly, nucleic acid was extracted from the patients' urine samples using the QIAsymphony DSP Virus/ Pathogen Kit (Qiagen, Inc., Valencia, CA) in combination with the QIAsymphony instrument (Qiagen, Inc.). Nucleic acid from patients' whole blood and fed breast milk was prepared using the QIAsymphony DSP DNA Kit (Qiagen, Inc.) in combination with a QIAsymphony instrument (Qiagen, Inc.). Urine was collected from disposable diapers, and nucleic acid was extracted from this urine using the QIAamp DNA Investigator Kit (Qiagen, Inc.). The JRCS stores and retains repository blood samples from all donors, with the specimens consisting of samples that have been separated into clot and serum fractions. We also prepared nucleic acid from clot and serum fractions of repository blood samples related to transfused blood components. The blood clot was pulverized using the Biomusher V (Nippi, Inc., Tokyo, Japan). Subsequently, nucleic acid was prepared from the disrupted clot using the QIAsymphony DSP DNA Kit in combination with a QIAsymphony instrument, as previously described. Our previous study showed that the efficiency of nucleic acid isolation from the blood clot of a repository blood sample was almost equal to that from the buffy coat. 18 Nucleic acid extraction from serum fractions was performed in the same way as for urine samples. PCR for CMV was performed using the artus CMV QS-RGQ Kit (Qiagen, Inc.) along with a Rotor-Gene Q instrument (Qiagen, Inc.), in accordance with the manufacturer's instructions. The detection sensitivity of the CMV QS-RGQ Kit for CMV DNA was 69.7 IU/mL (95% limit of detection [LOD] ) for plasma and 269.9 IU/mL (95% LOD) for whole blood.
Sequence analyses of CMV hypervariable regions
DNA sequences of the UL139 and UL146 genes were determined as described previously. 19 Briefly, nested PCR was performed using the previously described primer sets.
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PCR products were purified using the QIAquick PCR Purification Kit (Qiagen, Inc.) in accordance with the manufacturer's instructions. UL139 and UL146 gene sequences then were determined using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and analyzed using a 3130xl Genetic Analyzer (Applied Biosystems). The sequences of CMV genes from patients' urine/ blood then were compared with those from fed breast milk or repository blood samples using GENETYX Version 12 software (GENETYX Corp., Tokyo, Japan). To clarify the sequence variability of these genes, CMV genotypes found in patient specimens and fed breast milk were subjected to phylogenetic analyses, and trees were created using Mega 6.0 software. 20 
Detection of CMV antibody
Anti-CMV antibody levels were qualitatively evaluated in plasma fractions of patients' blood and serum fractions of repository blood samples. Specifically, anti-CMV IgM was assessed using the Enzygnost Anti-CMV/IgM assay (Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany), and anti-CMV IgG was assessed using the antiviral antibody EIA Cytomegalo IgG assay (Denka Seiken Co., Ltd., Tokyo, Japan), in accordance with the manufacturers' instructions.
RESULTS
Incidence of acquired CMV infection in preterm infants (Study A)
Sixty-five preterm infants were enrolled during the study period. The median (range) of gestational age and birth weight of the enrolled infants were 30 (23-33) weeks and 1206 (320-2112) g, respectively. No infants yielded a positive result in urine screening (0% congenital CMV infection). The incidence of acquired CMV infection was 6.2% (95% confidence interval, 1.7%-15.0%) (4/65) at a median (range) assessment age of 34 (21-85) days of age (35 [32-37] weeks of corrected gestational age) (Fig. 1) . Two of the four patients with acquired CMV infections had received blood transfusions and were analyzed in Study B (Nos. 12 and 13 in Table 1 ). One of these patients (No. 13) developed CMV disease. Among 52 mothers who were screened for anti-CMV IgG antibodies, 28 (54%) were seropositive; this subgroup included the mothers of all of those patients with acquired CMV infections.
Characteristics of VLBWIs with CMV disease (Study B)
Although breast milk has been thought to be a major source of CMV transmission to VLBWIs, TT-CMV, not BM-CMV, is presumed in patients who receive blood transfusions. Therefore, we initiated Study B to determine the precise CMV transmission routes in TT-CMV-suspected VLBWIs. At the start of the study, we distributed a written request to hospitals all over the country asking for their cooperation in the study by providing us with breast milk specimens from TT-CMV-suspected cases. As a result, the number of TT-CMV-suspected cases reported to the JRCS was increased, and we were able to obtain fed breast milk for most of these cases. Clinical features of the VLBWIs examined in this study are summarized in Table 1 . Two infants who participated in Study A also were included (Nos. 12 and 13 in Table 1 ). All but one (No. 12) demonstrated various clinical symptoms and abnormal results in laboratory tests. Definitive diagnosis of CMV disease was obtained by the detection of CMV DNA in urine (10 patients), blood (2 patients), or both fluids (2 patients). Eight patients were tested for anti-CMV IgM and shown to be seropositive. We also tested six of these eight patients for the presence of anti-CMV IgG; all six were seropositive. The mean number of breast milk feeding days was 55 (range, 24-106) days. Six patients (Nos. 2, 5, 7, 10, 12, and 13) had been fed only frozen-thawed milk, whereas the remaining patients had been fed fresh milk alone or both fresh and frozen-thawed milk. Of the 18 patients in this study, 7 were treated with antiviral drugs, such as ganciclovir or valganciclovir. One patient died because of liver failure, which was reportedly unrelated to CMV disease.
Detection of CMV DNA in breast milk and transfused blood
The results of PCR for CMV in fed breast milk are shown in Table 2 . CMV DNA was detected in fed breast milk in 12 of 14 cases, for which breast milk specimens were available. For one case (No. 9), CMV DNA was detected in fed breast milk during testing by the hospital, but not during testing by the JRCS.
We performed CMV PCR on repository blood samples related to all blood products that had been transfused into 14 of the 18 patients (Nos. 1-5, 9, and 11-18) ( Table 2 ). The consensus in the field was that the remaining four cases, for which fed breast milk had been first examined and the diagnosis of BM-CMV had previously been made, were not subjected to testing of their repository blood samples. In all 14 patients, the transfused blood products included products from anti-CMV IgG-positive donors. However, CMV DNA was detected in only three of the repository blood samples examined (Nos. 1, 15, and 16).
Sequence analyses of CMV UL139 and UL146 genes in breast milk
Next, we examined either of two variable CMV genes, UL139 and UL146, for homology between the respective sequences recovered from each patient's urine/blood and fed breast milk. This analysis was performed for all 12 cases in which CMV DNA was detected in fed breast milk. To clarify the sequence variability of these genes, we first evaluated the sequence-matching rates in every combination of two breast milk samples for the UL139 gene and (separately) for the UL146 gene. Sequence-matching rates ranged from 58.5 to 100% for UL139 and from 44.6 to 99.9% for UL146 (Tables 3 and 4 , respectively), indicating that there was some degree of sequence diversity for these genes, although several combinations showed a high matching rate of >98% for a given gene. Most CMV strains were distinguishable when we evaluated strain homology while combining the sequence data from both genes; CMV strain combinations with high homology in one gene typically showed low homology in the other gene. These results encouraged us to investigate the causal relationship between fed breast milk and CMV infection by comparing CMV nucleotide sequences in the milk with those in the respective patient.
As shown in Table 2 , DNA sequence-matching rates for both genes (when comparing between the patients' urine/ blood and fed breast milk) were 100% in 10 patients and nearly 100% in one patient (No. 12). For patient No. 2, sequence analysis for the UL146 gene could not be performed because of a low viral load in the patient's blood; however, the DNA sequence-matching rate was 100% for the UL139 gene in this patient. Patient No. 1 has been previously described. 19 In this patient, CMV DNA was also detected in a related repository blood sample. However, DNA sequence-matching rates between the patients' urine/blood and the repository blood sample were low (64.6 and 68.6% for the UL139 and UL146 genes, respectively). 19 Using the results of sequence analyses, phylogenetic trees then were created for CMV detected in the patients' specimens and fed breast milk, while also incorporating reference strain sequences. These phylogenetic analyses showed that the CMV sequences obtained from each patient clustered with those from the respective breast milk specimen ( Fig. 2A and 2B) .
DISCUSSION
In the first study (Study A), we demonstrated that the incidence of acquired CMV infection was 6.2%, as assessed in patients fed frozen-thawed breast milk and/or formula milk in a Japanese neonatal care unit. Lanzieri et al. reported incidences of 19% in infants fed fresh breast milk and 13% in infants fed frozen-thawed breast milk. 7 In a prospective cohort study, Josephson et al. reported an incidence of 5.4% in infants fed frozen-thawed breast milk, 4 a value similar to that (6.2%) obtained in the present report. The difference in incidence may be explained by the proportion of CMVseropositive mothers in the study cohorts. Lanzieri et al. only analyzed infants from anti-CMV antibody-positive mothers, whereas Josephson et al. and the present study included infants from CMV-seronegative mothers (who constituted approx. 25%-46% of the mothers).
In the second study (Study B), we performed sequence analyses of CMV hypervariable regions to evaluate CMV transmission routes, with the intent of comparing the risk of BM-CMV with the risk of TT-CMV. Eighteen VLBWIs examined in this study were confirmed to be infected with CMV after blood transfusion. However, in 12 of 14 cases, for which breast milk was provided, CMV DNA was detected in fed breast milk, whereas CMV DNA was not detected in the clot fraction of repository blood samples in 11 of 14 cases examined. More important, UL139 and UL146 gene sequences from fed breast milk were highly homologous with those from the respective patient's urine/blood in each of these 12 cases. These data strongly suggested that these patients had BM-CMV.
In two cases (Nos. 9 and 14), fed breast milk was negative for CMV DNA. Because repository blood samples related to blood components that had been transfused into these patients also were negative for CMV DNA, it is possible that CMV had been transmitted through an unknown route other than breast milk or blood products. However, with respect to patient No. 9, the breast milk was CMV positive in the testing conducted at the hospital; thus, the possibility of BM-CMV remains for this case. It is conceivable that the viral load in this milk specimen was at or below the detection limit at the time when we performed the assays and that differences in the sensitivities of the CMV detection systems (hospital vs. JRCS) yielded conflicting results.
From 2010 to 2014, before the initiation of the present study, 17 TT-CMV-suspected cases, in which breast milk was not provided, were reported to the JRCS. In these cases, CMV PCR results were negative in all of the corresponding repository (donor) blood samples, suggesting that these cases were not actually TT-CMV cases (unpublished data). Therefore, it is likely that the incidence of TT-CMV is extremely low.
It is important to clarify whether transfusion with blood components prepared from CMV DNA-positive donors can cause TT-CMV. Three patients (Nos. 1, 15, and 16) developed CMV disease after transfusion with leukoreduced blood products from CMV DNA-positive donors. The first patient (No. 1) was subsequently diagnosed as having BM-CMV on the basis of the results of sequence analysis. 19 In the second patient (No. 15), sequence analysis of repository blood samples was not performed because of low viral load.
In the third patient (No. 16), TT-CMV was ruled out because the UL139 and UL146 gene sequences recovered from the repository blood samples did not match those in the patient's urine (matching rate: UL139, 89.3%; UL146, 78.1%). Unfortunately, the diagnosis of BM-CMV could not be made in the last two patients (Nos. 15 and 16) because breast milk was not provided for testing. Although we have analyzed only a few cases thus far, we believe that the risk of TT-CMV is low even when blood products from CMV DNA-positive donors are transfused. Because we use leukoreduced blood products, leukoreduction appears to decrease the risk of TT-CMV in such blood products. Interestingly, a recent report showed that TT-CMV was not observed in 39 nonimmunocompromised adults who had been transfused with blood products from CMV DNApositive donations.
14 In both Study A and Study B, all examined mothers of CMV-infected infants were positive for anti-CMV antibody. However, when the mother of an infected infant is CMV seronegative, transfusion products or other CMV-infected individuals should be considered as likely sources of infection. Thus, it would be of great interest to elucidate the incidence of CMV infection in infants with CMV-seronegative mothers.
Our results emphasize the value of using hypervariable CMV gene sequences to estimate the source of CMV transmission in VLBWIs. We found, however, that some sequence combinations had extremely high homology. Notably, five clusters for UL139 (No. 1, Nos. 2 + 4 + 8 + 10 + 11 + 12 + 13, Nos. 3 + 6, No. 5, and No. 7 in Table 3 ) and six clusters for UL146 (Nos. 1 + 11, No. 3, Nos. 4 + 13, Nos. 5 + 6 + 8, Nos. 7 + 12, and No. 10 in Table 4) were determined. Our results are in line with those of Bradley et al., who described 8 and 14 genotypes for UL139 and UL146, respectively, according to the genes' nucleotide sequences. 15 Given that sequence clusters with high homology were found even in a few CMV isolates in our study, it is crucial to evaluate the combination of the two sequences. We could, however, find identical CMV strains among those collected from unrelated conditions, even when sequence variability was evaluated using the combination of the two genes, as verified in Nos. 4 and 13. Considering the limited sequence variability in these genes, it remains theoretically possible that the patients in our study were infected via a route other than breast feeding, after infection by CMV strains bearing the same sequences as those in breast milk. Therefore, additional genes or regions with high sequence variability should be sought in the CMV genome to facilitate investigations of the causal relationship in CMV disease. UL73 and UL74 might be such candidate regions, given that previous studies have shown that the sequences of these regions vary among CMV strains. 21, 22 Frozen-thawed breast milk is an attractive option for the prevention of BM-CMV because the freeze-thaw process might reduce the level of replication-competent virus. In fact, Balcells et al. recently showed that the CMV transmission rate was lower in VLBWIs nourished with frozenthawed milk than in those fed with fresh milk. 6 However, several other reports have failed to validate the clinical effectiveness of this method 4, 5 ; thus, its utility remains controversial. 7 In fact, in our study, six patients (Nos. 2, 5, 7, 10, 12, and 13) who were fed only frozen-thawed milk nonetheless acquired BM-CMV. In addition, in our incidence study (Study A), four patients acquired CMV even when fed only with frozen-thawed breast milk. The effectiveness of other methods, such as microwave treatment, also has been examined 23 ; however, methods for these alternative treatments have not been formally established. Given that a high CMV viral load is often detected in breast milk and, therefore, that many CMV cases in VLBWIs might be BM-CMV, establishing an effective strategy for CMV reduction in breast milk remains an important goal.
In conclusion, the incidence of acquired CMV infection was 6.2% in a Japanese neonatal care unit. Our findings strongly suggest that CMV is transmitted principally via breast milk and that TT-CMV is rare. When VLBWIs develop CMV disease, sequence analysis of hypervariable CMV genes in the patients' blood/urine, mothers' breast milk, and/or transfused blood is valuable for evaluating infection routes. Furthermore, evaluation of precise transmission routes by such analyses is expected to facilitate the investment of public resources for the prevention of the most critical transmission route.
